Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has received notice from the U.S. National Highway Traffic Safety Association (NHTSA) for the approval of its BreathLogix “Workplace Series” (WS) alcohol breathalyzer. The BreathLogix WS alcohol screening device (see Figure 1) was recently evaluated by the Volpe Transportation Systems Center and determined to meet the United States Department of Transportation (USDOT) model specifications for breath alcohol screening devices (ASD). The BreathLogix WS will be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices. The USDOT and NHTSA are the primary government entities charged with the safety of motor vehicle operation and road travel in the United States. BreathLogix rapidly checks breath alcohol, simultaneously takes a photo of the user, alerts managers in real-time to help avoid injury and damage due to alcohol impairment.
The Company is advancing discussions with potential distributors for the sales and marketing of the BreathLogix series of alcohol devices in the U.S. and elsewhere. BreathLogix is targeted for a range of applications and virtually all safety sensitive industries including, construction, transportation, healthcare, manufacturing, warehouse settings, 24/7 programs, sea vessels, docks, restaurants and airlines.
Figure 1. BreathLogix Workplace Series Alcohol Screening Device
Figure 1. BreathLogix Workplace Series Alcohol Screening Device
Figure 2. BreathLogix Alcohol Screening Device
Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
BreathLogix Alcohol Screening Devices
BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.
BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of distributors; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
